BioNTech (NASDAQ:BNTX) Trading Down 1.3% – What’s Next?

Shares of BioNTech SE (NASDAQ:BNTX) were down 1.3% during mid-day trading on Wednesday . The company traded as low as $115.51 and last traded at $115.91. Approximately 88,213 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 805,779 shares. The stock had previously closed at $117.39.

Analysts Set New Price Targets

BNTX has been the topic of several analyst reports. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and set a $150.00 target price on shares of BioNTech in a research report on Monday, November 18th. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. Finally, UBS Group raised their target price on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $140.76.

BioNTech Trading Down 2.5 %

The stock has a market cap of $27.20 billion, a P/E ratio of -54.49 and a beta of 0.22. The firm’s 50 day simple moving average is $113.66 and its two-hundred day simple moving average is $100.66. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the prior year, the firm earned $0.73 EPS. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. As a group, equities research analysts predict that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC grew its stake in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after buying an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC acquired a new position in shares of BioNTech during the third quarter valued at $59,485,000. Candriam S.C.A. grew its position in shares of BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after acquiring an additional 341,311 shares during the period. Finally, Braidwell LP bought a new stake in BioNTech in the 3rd quarter valued at about $29,425,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.